仅仅是一匙的甲福明,就能帮助药物消化
Theophilos Tzaridis1, Robert J Wechsler-Reya1,2
1Cancer Genome and Epigenetics Program, NCI-Designated Cancer Center, Sanford Burnham, Prebys Medical Discovery Institute, La Jolla, California, USA.
The Journal of clinical investigation
|March 15, 2024
概括
一种新的三重疗法,结合了帕克萨利西布,甲福尔明和素,通过减轻副作用和克服耐药性来治疗扩散内在结质瘤 (DIPG),从而改善了临床前模型中的生存率.
科学领域:
- 神经瘤学神经瘤学
- 药理学 药理学是指药理学的学科.
- 癌症生物学 癌症生物学
背景情况:
- 扩散内在庞丁质瘤 (DIPG) 是一种高度攻击性的儿科脑瘤,治疗选择有限.
- 目前用于DIPG的单疗法和组合策略往往导致严重的毒性和有限的疗效.
- PI3K/mTOR途径代表了DIPG.的潜在治疗漏洞.
研究的目的:
- 为DIPG开发一种新的药物组合,减轻副作用并克服治疗耐药性.
- 在DIPG模型中研究涉及paxalisib,甲福林和酶氨酸的三重疗法的疗效.
主要方法:
- 携带DIPG的小鼠接受了paxalisib的治疗,然后与甲福林结合,以解决高血糖的副作用.
- 蛋白质激酶C (PKC) 信号被分析为对帕克萨利西布-美特福林组合抗性的机制.
- 添加PKC抑制剂恩扎斯图林,以创建三重疗法,并评估生存结果.
主要成果:
- 帕克萨利西布单一治疗显示出初始反应,但在DIPG小鼠中引起严重的高血糖症.
- 结合帕克萨利西布和甲福明可以减少高血糖,但导致PKC信号增加,表明耐药性.
- 三重疗法 (帕克萨利西布,甲福尔明和恩扎斯图林) 在携带DIPG的小鼠中显著改善了生存率.
结论:
- 针对PI3K/mTOR途径和PKC信号的三重药物组合为DIPG提供了一个有前途的治疗策略.
- 这种方法有效地减轻了严重的副作用,克服了抵抗机制,改善了生存率.
- 这项临床前研究为改善DIPG和潜在的其他脑瘤治疗结果提供了基础.
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
01:23Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:16Insulin: Dosing Regimen and Adverse Effects
170
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
170
01:17Oral Hypoglycemic Agents: Sulfonylureas
208
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
208